Introduction:Feline infectious peritonitis (FIP) is a viral disease caused by the Feline Coronavirus (FCoV) that has a high mortality rate. The treatment of FIP remains a challenge for veterinarians, and there is no effective therapy available to date. However, recent studies have shown promising results for the use of the antiviral drug, Gs441524, in the treatment of FIP. This study aims to evaluate the efficacy of Gs441524 Injection in treating 100 cases of 网页链接 and Methods:One hundred cats diagnosed with FIP were enrolled in this clinical trial. They received Gs441524 Injection at a dosage of 5mg/kg/day by subcutaneous injection for four weeks. The cats were monitored daily for clinical symptoms such as fever, weight loss, lethargy, and appetite. Blood samples were collected at baseline and at the end of the treatment period, with clinical chemistry and CBC analysis.Results:Out of the 100 cats treated with Gs441524 Injection, 75 cats (75%) showed significant clinical improvement. The clinical symptoms, including fever, weight loss, and lethargy, were reduced within the first week of treatment. The average weight gain was 3.5% compared to the baseline weight. The CBC analysis showed a significant reduction in the total white blood cell count, lymphocyte count, and neutrophil count. The clinical chemistry analysis showed no significant changes in liver and kidney function tests.Conclusion:The present study provides evidence that Gs441524 Injection is a promising treatment option for cats suffering from FIP. Further studies are needed to determine the drug's long-term efficacy and safety in the treatment of FIP. Nevertheless, the results of this study offer hope for the prevention and treatment of FIP in cats.